none taken kates. gd to see u on here and appreciate ur ta on this amongst others.
like you mentioned, you really have to be holding shares before ann are out. a licensing agreement will easily double the sp within a day for micro-cap pharma coy.
from e exchange of emails as well as previous ann from coy, i do expect more license agreements with big names by years end and Dr Cummings doesnt rule out one before the AGM.
southern cross equities recommends a spec buy in their report; valuing Anteo at $0.13 per share base case and $0.24 optimistic case using a high-discount-rate (ie 25%) DCF valuation. their target price of $0.13 sits at their base case valuation. they see potential for a rerating of Anteo as further licensing deals emerge and early revenue is generated from Bangs and Merck.
none taken kates. gd to see u on here and appreciate ur ta on...
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ADO (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
2.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $49.36M | |||
| Open | High | Low | Value | Volume |
| 2.0¢ | 2.1¢ | 2.0¢ | $33.18K | 1.658M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 2717347 | 2.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.1¢ | 723484 | 6 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| ADO (ASX) Chart |